MSD and Moderna’s individualised cancer vaccine mRNA-4157 has shown impressive efficacy in a phase 2b trial in skin cancer melanoma, leaving the partners speculating about a possible regulatory ...

Venture capital group Flagship Pioneering has raised $2.6 billion to support the development of around 25 startups operating in human health, sustainability, and artificial intelligence, with ...